Sandoz Inc. is the fourth company to opt to settle with AbbVie Inc. rather than battle over its vast Humira (adalimumab) patent portfolio.
Under the terms of the agreement, announced Oct. 11, Sandoz will be able to launch its proposed biosimilar Hyrimoz in...






